Successful Response to Microbiota-Based Drug RBX2660 in Patients with Recurrent Clostridium Difficile Infection is Associated with More Pronounced Alterations in Microbiome Profile

Benzer Materyaller

• 669. Twelve-Month Durability of Microbiota-Based Therapy RBX2660 for Prevention of Recurrent Clostridium difficile Infection
  Yazar:: Jones, Courtney, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• 670. VRE Clearance in Patients with Recurrent Clostridium difficile Infection Following Treatment with Microbiota-Based Drug RBX2660
  Yazar:: Hau, Heidi, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• 1950. Prevention of Recurrent Clostridium difficile at Six Months Following Treatment With Microbiota-Based Therapy RBX2660: Durability Results From a Phase 2 Open-Label Study
  Yazar:: Mische, Sarah, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)
• Restoration of Bacterial Microbiome Composition and Diversity Among Treatment Responders in a Phase 2 Trial of RBX2660: An Investigational Microbiome Restoration Therapeutic
  Yazar:: Blount, Ken F, ve diğerleri
  Baskı/Yayın Bilgisi: (2019)
• 1966. Evaluating a Prototype Microbiome Health Index (MHI) as a Measure of Microbiome Restoration Using Data Derived From a Published Study of Fecal Microbiota Transplant (FMT) to Treat Recurrent Clostridium difficile Infections (rCDI)
  Yazar:: Blount, Ken, ve diğerleri
  Baskı/Yayın Bilgisi: (2018)